Misleading hepatitis B test results due to intravenous immunoglobulin administration: Implications for a clinical trial of rituximab in immune thrombocytopenia

Transfusion

Volumn 50, Issue 12, 2010, Pages 2577-2581

  Arnold, Donald M ^a   Crowther, Mark A ^a   Meyer, Ralph M ^a   Carruthers, Julie ^a   Ditomasso, Julie ^a   Heddle, Nancy M ^a   McLeod, Anne ^a   Kelton, John G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RITUXIMAB;

ADULT; ANTIGEN DETECTION; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE THROMBOCYTOPENIA; INTRAVENOUS ADMINISTRATION; MALE; REPEAT PROCEDURE; RETROSPECTIVE STUDY; SEROPREVALENCE; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CASE-CONTROL STUDIES; DIAGNOSTIC ERRORS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SEROLOGIC TESTS;

EID: 78650034473     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02766.x     Document Type: Article

References (25)

1. Cooper N, Arnold DM,. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010; 149: 3-13.
2. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM,. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-74.
3. Dervite I, Hober D, Morel P,. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
4. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E,. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
5. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK,. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
6. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
7. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, Huebsch L, Hume H, McLeod A, Meyer R, Moltzan C, Nahirniak S, Nantel S, Pineo G, Rock G,. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21 (2 Suppl 1): S9-56. (Pubitemid 46505088)
8. O'Brien SF, Xi G, Fan W, Yi QL, Fearon MA, Scalia V, Goldman M,. Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008; 48: 2323-30.
9. Urbani S, Fagnoni F, Missale G, Franchini M,. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med 2010; 48: 23-9.
10. Borowitz SM,. Positive hepatitis serologies with treatment for Kawasaki syndrome. Arch Dis Child 1993; 68: 151.
11. Prohaska W, Wolff C, Schluter K, Koster-Eiserfunke W, Korner MM, Kleesiek K,. Immunoglobulin preparations from hepatitis C antibody-positive plasma donors: influence on diagnosis and risk of infection in heart transplant recipients. Clin Investig 1992; 70: 573-8.
12. Boschetti N, Stucki M, Spath PJ, Kempf C,. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol 2005; 29: 333-44.
13. Neunert CE, Bright BC, Buchanan GR,. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer 2008; 51: 513-6.
14. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG,. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
15. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB,. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-9.
16. Liang R,. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-53.
17. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F,. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-5.
18. Hanbali A, Khaled Y,. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009; 84: 195.
19. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM,. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-9.
20. Sarrecchia C, Cappelli A, Aiello P,. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-91.
21. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den NE, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C,. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
22. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P,. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
23. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R,. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115: 2755-62.
24. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P,. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
25. Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ,. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med 2009; 37 (1 Suppl): S69-74.